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DOI 10.1016/j.ccr.2011.08.013SUMMARYUsing a mouse model of ependymoma—a chemoresistant brain tumor—we combined multicell high-
throughput screening (HTS), kinome-wide binding assays, and in vivo efficacy studies, to identify potential
treatments with predicted toxicity against neural stem cells (NSC). We identified kinases within the insulin
signaling pathway and centrosome cycle as regulators of ependymoma cell proliferation, and their corre-
sponding inhibitors as potential therapies. FDA approved drugs not currently used to treat ependymoma
were also identified that posses selective toxicity against ependymoma cells relative to normal NSCs both
in vitro and in vivo, e.g., 5-fluorouracil. Our comprehensive approach advances understanding of the biology
and treatment of ependymoma including the discovery of several treatment leads for immediate clinical
translation.INTRODUCTION
Advances in cancer therapy have been made by testing empiric
combinations of treatments in patients with histologically similar
tumors. This clinical research has been supplemented by labora-
tory studies of human cancer cell lines and xenografts aimed at
identifying therapies. Although this approach has reduced
deaths from some common malignancies (Berry et al., 2005;
Pui et al., 2004), it is inherently inefficient, failing to account for
the different molecular subtypes that populate cancers, andSignificance
Trial therapies for rare cancers are usually selected empirically
further by a lack of accurate preclinical models, and small patien
evidence-based approaches to select and prioritize trial treatm
and in vivo efficacy studies, we interrogated an accurate mous
comprehensive approach identified kinases not known to ma
dicted NSC toxicity for immediate clinical translation. This appr
ical trials among patients with specific subtypes of cancer.
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from each therapy. This process is especially inadequate for
developing treatments of rare cancers that have few patient
numbers and limited preclinical tools.
Ependymomas are rare tumors of the brain and spinal cord
that are incurable in up to 40% of cases (McGuire et al., 2009;
Merchant et al., 2009). Treatment of this disease has changed
little over the last 40 years and is essentially limited to surgery
and radiation. Chemotherapy has not impacted survival from
ependymoma, but the rarity of the disease and lack of preclinicaland often fail. The poor efficiency of this process is limited
t numbers thatmay include distinct subtypes.More rational,
ents are needed. Using HTS, kinome-wide binding assays,
e model of a specific subtype of human ependymoma. This
intain ependymoma and several treatment leads with pre-
oach holds significant promise to prioritize therapies for clin-
c.
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Foreman, 1999; Gilbert et al., 2010).
Histologic similarities between ependymomas from the
different regions of the central nervous system (CNS) have led
investigators to treat these tumors as a single entity. But these
tumors include discrete subtypes that will likely require different
therapies (Johnson et al., 2010; Taylor et al., 2005). To develop
more rational treatments of ependymoma, we are generating
mouse models of each disease subtype (Johnson et al., 2010).
The first of these, mEPEphb2, faithfully recapitulates the histology
and transcriptome of one form of human cerebral ependymoma
(subtype-D), making it an attractive tool for developing treat-
ments for this specific group of patients.
Recent evidence suggests that some cancers, including epen-
dymomas, contain stem-like cancer cells that are both sufficient
and required to propagate the disease (Johnson et al., 2010;
Lapidot et al., 1994; Singh et al., 2004; Taylor et al., 2005). There-
fore, the most effective treatments of these cancers are likely to
include drugs that kill these cells (Zhou et al., 2009). However,
ependymoma stem-like cells are remarkably similar to the
normal NSCs from which they arise (Johnson et al., 2010), sug-
gesting such treatments may also be toxic to developing tissues.
Developmental toxicities are a particular concern when treating
children with cancer whose organ systems are immature (Kimura
et al., 2008). Our ependymoma model system generates tumors
from isolated NSCs, allowing the conduct of comparative drug
toxicity studies. The goal of the current study was to employ
this mouse model system in a multiplatform, in vitro and in vivo
drug development approach to identify subtype-specific thera-
pies with predicted stem cell toxicity.
RESULTS
High-Throughput Screen (HTS) for Predicting Efficacy
and Toxicity
Cells isolated from mEPEphb2 ependymomas as well as distinct
variants of mouse NSCs, maintain their functional and molecular
identity when passaged clonally under conditions that promote
stem cell growth (Johnson et al., 2010). As a first step to identify
treatments of ependymoma, we adapted these cultures to
perform in a HTS campaign that detected compound toxicity
against normal andmalignant stem cells with high reproducibility
and sensitivity (Figure 1; Figure S1; Supplemental Experimental
Procedures available online).
We screened a total of 7890 (5303 unique) compounds ob-
tained from seven separate sources, divided among four libraries
(Figure 1A): a ‘‘bioactive’’ library that included 5600 (3161 unique)
bioactive compounds, natural products, and known drugs;
a ‘‘kinase-scaffold’’ library composed of 1648 compounds
designed using kinase inhibitor pharmacophore models;
GlaxoSmithKline’s Published Kinase Inhibitor Set (GSK-PKIS)
composed of 367 kinase inhibitor tool compounds with good
bioavailability and known specificity; and a Food and Drug
Administration (FDA) library that included 275 FDA approved
compounds that were enriched for anticancer and neurologically
active drugs.
We first screened all compounds in the bioactive library, each
at 8 mM concentration. This primary screen was conducted
against mEPEphb2 cells, as well as wild-type (NSCwt), andCanInk4a/Arf/ (NSCnull) mouse embryonic forebrain NSCs—the
initiating cell of mEPEphB2 tumors (Johnson et al., 2010). To
increase the probability of identifying ependymoma-specific
therapies, we also screened a nonependymoma mouse brain
tumor that we generated by transducing NSCnull with the intra-
cellular domain of NOTCH1 (mBTNICD1; Figure S1). The scatter-
plot of control and test compound activity in this primary screen
demonstrated a good separation between signal and noise for
each cell type (Figure 1B). Potency was then assessed in a con-
centration response secondary screen for all compounds in the
bioactive library that demonstrated R75% activity against any
of the four cell types. This secondary screen was performed in
triplicate using all four cell types. To assess the fidelity of the
primary screen, we also included in the secondary screen an
additional 254 compounds that demonstrated a range of primary
screen activities <75%. Receiver operator characteristic (ROC)
analysis of these data demonstrated good discriminatory power
for each cell type, and indicated that a primary screen threshold
of R50% activity would detect most true positives (Figure 1C).
Having validated our primary and secondary screen using the
bioactive library, we completed HTS of the kinase-scaffold,
GSK-PKIS, and FDA libraries.
A total of 634 unique compounds across the four libraries, rep-
resenting diverse drug classes, progressed from primary to
secondary screening (Figure 1D). In all, 2.6% (n = 140/5303) of
compounds displayed anti-mEPEphb2 secondary screen activity
(Figure 2). Since our HTS strategy included nonependymoma
tumor cells and NSCs, we were able to refine our classification
of compound activity (Table S1). To this end, we determined
for each cell type, the average ‘‘effective concentration’’ of
each compound that inhibited cell growth by 50% relative to
control treatment (EC50). The data were then used to identify
compounds withR2-fold potency against mEPEphb2 than other
cells (0.08%, n = 4/5303; mEPEphb2 selective); equally potent
against mEPEphb2 and mBTNICD1 cells relative to NSCs (0.04%,
n = 2/5303; tumor selective); equally potent against all four cell
types (2.5%, n = 134/5303; equipotent); R2-fold more potent
against mBTNICD1 relative to all other cells (0.2%, n = 13/5303;
mBTNICD1 selective);R2-fold more potent against NSCs (NSCwt
and/or NSCnull) relative to tumor cells (0.8%, n = 42/5303; NSC
selective); inactive against mEPEphb2 cells relative to all other
cells (0.1%, n = 7/5303; mEPEphb2 inactive); and inactive against
all four cell types (91%, n = 4809/5303; inactive).
HTS Identifies Cell-Selective Activity that Varies
with Drug Mechanism of Action
As expected, compounds with activity against mEPEphb2 cells
(mEPEphb2 selective, tumor selective, and equipotent) were
significantly enriched for anti-cancer drugs (Fisher’s exact p =
1.9 3 107: Bonferroni correction threshold, p = 0.0016), but
they displayed patterns of cell-selective activity that varied
according to their mechanism of action (Figures 2 and 3). Almost
all topoisomerase II inhibitors (p = 7.6 3 1009) and microtubule
poisons (p = 4.0 3 1007) were equipotent against the four cell
types. In contrast, dichotomous activity was observed among
antimetabolite anticancer compounds. Antimetabolites that
incorporate into DNA and disrupt normal DNA synthesis or
methylation, e.g., decitabine, were all NSC selective (p = 5.0 3
1009), while inhibitors of thymidylate synthase (TYMS) and/orcer Cell 20, 384–399, September 13, 2011 ª2011 Elsevier Inc. 385
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Figure 1. Compounds and Quality Control of the High-Throughput Screen
(A) Sources of compounds used in the screen.
(B) Scatter plot of percent primary screen activity (relative to vehicle) of positive controls (green) negative controls (red) and test compounds (black) for all four
cell types.
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enriched for ependymoma-selective compounds (p = 5.0 3
1009). Indeed, three of the four ependymoma-selective
compounds detected in the entire HTS were in this class:
5-FU, the 5-FU precursor 5-fluoro-50-deoxyuridine, and the
5-FU derivative carmofur.
The fourth ependymoma-selective agent identified in our
HTS—the ionophore beta-escin—disrupts normal membrane
ion exchange. Interestingly, potassium ionophores were recently
identified as breast cancer stem cell selective inhibitors, sug-
gesting this drug class might have broad activity against malig-
nant stem cell populations (Gupta et al., 2009). Proteosome
or protein synthesis inhibitors included drugs that were NSC
selective, e.g., bortezomib, while anticholesterol drugs were
equipotent or tumor selective (Figures 2 and 3).
Integration of HTS and Kinome-Wide Binding Assays
Unmasks Pathways Important for Maintaining
Ependymoma Cells and NSCs
Active compounds detected by HTS were also enriched for
inhibitors of specific kinases (Figures 2 and 3), including inhib-
itors of: Epidermal Growth Factor Receptor (EGFR, n = 9/11
inhibitors screened; p = 1.0 3 1008); Insulin Growth Factor 1
Receptor (IGF1R, n = 5/5; p = 7.3 3 1007); Polo-like kinase
1 (PLK1, n = 5/5; p = 7.3 3 1007); Cyclin dependent kinase
2 (CDK2, n = 4/4; p = 1.0 3 1005); and Jun NH(2)-terminal
kinase 2 and 3(JNK2/3, n = 3/3; p = 0.0001). A single Glycogen
Synthase Kinase 3b (GSK3b) inhibitor also proved active in
secondary screening. The equipotent activity of EGFR inhibi-
tors is compatible with reports that these receptors conduct
critical signals in ependymoma and normal NSCs (Aguirre
et al., 2010; Geoerger et al., 2008; Gilbertson et al., 2002;
Mendrzyk et al., 2006); however, none of the other active
kinase inhibitors identified, or their target molecules, have
been suggested previously as treatments or drivers of ependy-
moma, respectively.
The finding that IGF1R and PLK1 inhibitors disrupt mEpEphb2
cell and NSC proliferation is especially noteworthy. IGF1R is
expressed at the apical surface of forebrain NSCs—the cell of
origin of cerebral ependymoma (Johnson et al., 2010)—and
activates NSC proliferation following binding of its ligand IGF2
that is contained within the cerebrospinal fluid (CSF) (Lehtinen
et al., 2011). Furthermore, elevated levels of IGF2 sufficient to
activate aberrant NSC proliferation are found in the CSF of
patients with brain tumors (Lehtinen et al., 2011). The prolifera-
tion of NSCs and ependymoma stem cells occurs via a process
termed asymmetric division by which the parent stem cell self-
renews: this process is critically dependent on cell polarity, cell
cycle timing, and mitotic spindle formation that are each regu-
lated by PLK1 (Johnson et al., 2010; Noatynska et al., 2010;
Wang et al., 2009). Thus, IGF1R and PLK1 inhibitors, of which
more than 18 are currently in Phase I or II clinical trial, are attrac-
tive candidates for ependymoma clinical trials (Lens et al., 2010;(C) ROC analyses showing the true (y axis) versus false (x axis) positive rates of p
curves in gray are calculated from 200 bootstrap simulations. Percent activity is
(D) Drug classes represented by the 634 compounds tested in secondary screen
See also Figure S1.
CanNeal and Sequist, 2010). Importantly, several other kinase inhib-
itors currently under clinical development were inactive against
mEPEphb2, e.g., BRAF inhibitors and BCR-ABL inhibitors, sug-
gesting these drugs should given a lower priority for clinical trial
in ependymoma.
In addition to inhibitors of known kinases, we also identified 13
equipotent orphan-kinase inhibitor scaffolds for which the
molecular target is not known (Figures 2 and 3). Identifying the
kinases targeted by these compounds could pinpoint further
cell signals critical for ependymoma cell survival, as well as
therapeutic approaches. Therefore, we subjected the four
most active kinase scaffolds (SJ000516613, SJ000517447,
SJ000517729, and SJ000517939; Figure 3) to competitive
binding assays against 442 human kinases (see Supplemental
Experimental Procedures). Kinase scaffolds were first screened
at a single fixed concentration (2.5 mM) against all 442 kinases
(Figure 4A). One or more kinase scaffolds bound 13 kinases
with >50% activity relative to controls. In keeping with our
HTS data, these included EGFR, Insulin Receptor-Related
Receptor (INSRR), and EPHB2: the latter transforms NSCs in
the mEPEphb2 model. To validate additional kinases as potential
drivers and drug targets of cerebral ependymoma, we
performed a series of six-point dose response binding assays
against kinases most tightly bound in the single concentration
assay. These data identified PIP5K1C, TTK, and YSK4 as
kinase targets of SJ000516613 and SJ000517729, with binding
Kds similar to their EC50s in whole-cell proliferation assays
(Figures 3 and 4B). RIOK2 and CK1d were bound by
SJ000517939 and SJ000517447, respectively, albeit at much
higher concentrations.
Integration of our HTS and kinome binding data showed that
57% (n = 25/44) of kinase inhibitors and scaffolds with activity
against ependymoma cells and NSCs, target critical compo-
nents of just three major cell pathways: the EGF, IGF and centro-
some cycle pathways (Figures 3–5). Nine inhibitors targeted
components of the centrosome cycle (Figure 5A), including
PLK1 (discussed above), and CDK2 and its direct substrate
TTK, that together regulate centrosome duplication (Cowan
and Hyman, 2006; Kasbek et al., 2007). Seven inhibitors target
the IGF pathway; including five direct inhibitors of IGF1R (Fig-
ure 5B and discussed above). Notably, gene expression profile
analysis showed that IGF1R expression is significantly upregu-
lated in mEPEphb2 cells relative to parental NSCs or mBTNICD1
cells (Figure 5C). Further, GSK2110236A, a potent inhibitor of
mEPEphb2 proliferation (Figure 3) and known IGF1R kinase inhib-
itor within the GSK-PKIS library, blocked IGF1R and its down-
stream signal in mEPEphb2 cells stimulated with IGF2 (Figure 5D).
Together, these data identify the EGF, IGF, and centrosome
cycle pathways as key signals for maintaining cerebral ependy-
moma and their corresponding inhibitors as lead candidate
targets of therapies. However, the equipotent activity of these
compounds in HTS should alert investigators to the possibility
of NSC-toxicities in clinical trials.ercent drug activity correlating the primary and secondary screens. The ROC
color-coded according to the right y axis.
s.
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Ependymoma In Vivo
To allow themost rapid translation of treatments from our HTS to
the clinic, we selected two FDA approved anticancer drugs for
our first sets of in vivo studies. 5-FU is a well-established chemo-
therapeutic for the treatment of certain cancers, e.g., colorectal
cancer (Douillard et al., 2000; IMPACT, 1995), but this drug has
not been tested formally in patients with ependymoma. The
ependymoma-selective activity of 5-FU in our HTS and relatively
low expression of TYMS (Figure 5C) —the principal cellular
target of 5-FU—in mEPEphb2 cells, suggest this drug as a rational
treatment of cerebral ependymoma (Longley et al., 2003). Simi-
larly, bortezomib—a reversible inhibitor of the 26S protea-
some—has not been tested against ependymoma in the clinic
but was highly potent against mEPEphb2 cells, and has activity
against a variety of cancers including brain tumors (Adams,
2004; Phuphanich et al., 2010; Richardson et al., 2003; Taniguchi
et al., 2009).
First, we tested the in vivo efficacy of 5-FU and bortezomib
using a robust orthotopic allograft model of mEPEphb2 ependy-
moma. 1.5 3 106 mEPEphb2 cells transduced with luciferin
(hereon, mEPEphb2-LUC) were injected stereotactically into the
brains of immunocompromised mice. Bioluminescence de-
tected brain tumors in these mice that conferred a median
survival of 31 days (n = 56 control mice) and displayed a histology
and gene expression profile indistinguishable from that of
mEPEphb2 (Figure 6, Figure S2). Mice bearing mEPEphb2-LUC
tumors were treated with eight different therapeutic regimens
(n R 10 mice per cohort; Table 1). 5-FU and bortezomib were
given intravenously at doses reported previously to be effica-
cious in cancer bearing mice (Houghton et al., 1996; Williamson
et al., 2009). 5-FU is usually given as a prolonged infusion in the
clinic; therefore, to simulate this, we also administered 5-FU via
subcutaneous Alzet pumps (Kamano et al., 1997). For compara-
tive purposes we also treated cohorts of mice with carboplatin,
topotecan, irinotecan, or carboplatin plus topotecan that have
produced clinical, but not durable, responses against ependy-
moma (Bomgaars et al., 2006; Bouffet and Foreman, 1999;
Kadota et al., 1999). Neither carboplatin nor irinotecan were
active against mEPEphb2 in our HTS, while topotecanwasmoder-
ately equipotent against all cells (EC50 = 0.2–0.7 mM; Figure 2). As
an additional test of the power of our HTS to predict in vivo
efficacy, we treated a cohort of mice with lapatinib that was
inactive in our HTS, but is currently undergoing clinical trials in
ependymoma. Each of these chemotherapies were adminis-
tered according to existing preclinical regimens (Gorlick et al.,
2009; Stewart et al., 2004; Thompson et al., 1997; Tonda et al.,
1996; Wagner et al., 2010) or schedules designed to generate
plasma levels in mice that are equivalent to those active in chil-
dren with brain tumors (Table 1). Each protocol group was paired
with a control group of five or more mice that were implanted
with mEPEphb2-LUC cells, treated with vehicle alone, and imaged
in parallel at weekly intervals by bioluminescence (Figure 6).Figure 2. Drug Class Network Tree of Cell Type-Specific Potencies of
Top figure shows compounds clustered according to major therapeutic indication
below. Activity was determined by dose response in secondary screening. Drug
right). See also Table S1.
CanIn keeping with the relative resistance of ependymoma to
chemotherapies and the results of our HTS, carboplatin,
topotecan, irinotecan and lapatinib were all inactive against
mEPEphb2-LUC brain tumors (Figure 6). In stark contrast, both
bortezomib and intravenous 5-FU halved the rate of
mEPEphb2-LUC tumor growth and significantly prolonged the
survival of mice harboring these tumors. These data support
our HTS as a relatively accurate tool for predicting in vivo drug
efficacy. In contrast to intravenous 5-FU, this drug was inactive
when delivered subcutaneously (Figure 6). To test if pharmacoki-
netic differences might account for the variation in efficacy
between intravenous and subcutaneous administered 5-FU,
we allowed mEPEphb2-LUC tumors to form around microdialysis
catheters in the brains of recipient mice and measured simulta-
neously the concentration of 5-FU in the plasma and tumor
following intravenous or subcutaneous drug administration
(Supplemental Experimental Procedures). Intravenous 5-FU
produced a concentration in brain tumors that peaked at
800 mM ± 79 SD, and remained above 10 mM for approximately
1 hr: an exposure profile shown by in vitro wash-out experiments
to kill 90% of mEPEphb2 cells (Figures 7A and 7B). In contrast,
subcutaneous infusions of 5-FU at our trial dose of
1.03 mg/kg/hr failed to generate detectable tumor drug levels
(data not shown). Experiments using the maximum amount of
5-FU deliverable via Alzet pumps (13 mg/kg/hr) maintained
5-FU tumor concentrations of approximately 10 mM for over
24 hr, but this schedule was unacceptably toxic (R20% weight
loss) precluding assessment of in vivo therapeutic efficacy.
Together these data identify bortezomib and 5-FU as potential
treatments of ependymoma and indicate that the mode of
administration of 5-FU should be given careful consideration
when planning the treatment of ependymoma.
HTS Predicts Patterns of 5-FU and Bortezomib NSC
Toxicity In Vivo
Our HTSwas designed to predict theNSC toxicity of compounds
as well as their efficacy against ependymoma. Since this infor-
mation could prove extremely useful when prioritizing agents
for clinical trials we sought to test in vivo the prediction from
our HTS, that bortezomib would be relatively more toxic than
5-FU to NSCs (Figures 2 and 3).
Assessing the relative toxicity of drugs in vivo is complex
because it is difficult to regulate drug levels in tissues, and tissue
damage can involve multiple cell types. Nevertheless, we
reasoned that the schedules of 5-FU and bortezomib that dis-
played equivalent efficacy against ependymomas in the brain
(Figure 6, difference in median survival p = 0.1 and no significant
difference in tumor growth at any time point) are clinically mean-
ingful schedules for comparative studies of NSC toxicity. We
treated nontumor-bearing mice with therapeutically equivalent
schedules of 5-FU, bortezomib, or vehicle control, and after 2
or 4 weeks of therapy, measured the rate of apoptosis, and
extent of doublecortin (DCX) positive neuroblast rests in the634 Compounds Subjected to Secondary Screening
and mechanism of action. (A)–(E) indicate the location of larger figures shown
labels are colored according to cell type activity as defined in the key (bottom
cer Cell 20, 384–399, September 13, 2011 ª2011 Elsevier Inc. 389
Figure 3. Patterns of Drug Class Sensitivity
among Cells
Dose-response curves reveal distinct patterns of
relative drug sensitivity among normal NSCs and
tumor cells. The structure of the corresponding
agent (and where appropriate molecular target) is
shown in each graph.
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apoptotic neuroblasts is an established feature of ischemic,
chemotherapeutic, and genetic damage to the SVZ (Baker
et al., 2006; Brown et al., 2003; Carle´n et al., 2009; Dietrich
et al., 2006; Jin et al., 2010). To provide an additional measure
of the cellular response to drugs we used Prom1+/C-L mice in
our studies: these mice express the LacZ reporter from the
Prom1 locus in NSCs, neuroblasts, and ependymal cells (Cos-
kun et al., 2008; Kriegstein and Alvarez-Buylla, 2009; Zhu
et al., 2009).
Following 2 weeks of therapy, the number of apoptotic cells in
the SVZ of 5-FU and bortezomib-treated mice was double
(12.0 ± 1.7 SEM, p < 0.05) and more than triple (22.2 ± 5.1
SEM, p < 0.005) that of controls (6.3 ± 1.2 SEM), respectively
(Figure 7E). Bortezomib also quadrupled the area of DCX+ neuro-
blast rests in the SVZ (6.0 mm2 ± 0.6 per mm ventricular surface
versus control = 1.5 mm2 ± 0.6 per mm ventricular surface; p <
0.005); but 5-FU therapy had no significant impact on DCX
labeling (2.2 mm2 ± 1.1 per mm ventricular surface). Both 5-FU
(35.1% ± 3.3% SEM, p < 0.05) and bortezomib (39.2% ± 2.8%
SEM, p < 0.005) increased the number of Prom1+ cells in the
SVZ at 2 weeks relative to controls (20.9 ± 2.4 SEM; Figure 7E).
Following 4 weeks of therapy, apoptotic and DCX+ labeling in the
SVZ of both 5-FU and bortezomib-treated mice returned to
control levels (Figure 7E); however, Prom1+ cell numbers
continued to rise in the SVZ of bortezomib-treated mice, reach-
ing >2.5 times that of controls by 4 weeks (57.8% ± 4.0% SEM
versus control = 19.4% ± 3.1% SEM, p < 0.0005; Figure 7E).
These cells included a mix of Prom1+/CD24+ ependymal cells,
as well as a large number of Prom1+/CD24- cells that likely repre-
sent NSCs and neuroblasts (Figure 7F). These data strongly
suggest that bortezomib is more damaging to the SVZ niche
than therapeutically equivalent doses of 5-FU, and provide
preliminary evidence that our HTS might be useful for predicting
the NSC toxicity of potential ependymoma therapies. Further
work is required to fully characterize the expanded Prom1+
SVZ cell population in drug-treated mice, and to determine the
clinical significance of histologic SVZ damage.
DISCUSSION
The approach described here should significantly advance
the efficiency and speed with which we discover and develop
treatments for rare cancers and cancer subtypes. Studies of
genetic mouse models have uncovered treatments for some
brain tumors (Romer et al., 2004; Rudin et al., 2009), but a lack
of ependymoma models has precluded similar efforts for this
disease. We describe an integrated, multiplatform, in vitro and
in vivo drug screen of an accurate mousemodel of ependymoma
(mEPEphb2), identifying the IGF, EGF, and centrosome cycle
pathways as key candidate regulators of subtype-D tumors, as
well as several treatment leads for the disease. We believe that
these treatments are significantly enriched for drugs that will
ultimately prove effective in patients because mEPEphb2 tumors
reproduce the histology, ultrastructure, and transcriptome of
subtype-D ependymoma with remarkable fidelity (Johnson
et al., 2010).
Ependymomas retain many of the biological properties of
their parent NSCs (Johnson et al., 2010). Therefore, many potentCanantiependymoma drugs may also be neurotoxic. This notion is
supported by the results of our HTS, in which the majority of
active agents, including molecular targeted therapies, were
equipotent against ependymoma and NSCs. Although similari-
ties between ependymoma and NSCs may mean that cancer-
selective agents are rare, our HTS system can identify these
drugs. This represents a significant advance for clinical trial
design. For example, ependymoma-selective agents (e.g.,
5-FU) may be paired with effective but less selective drugs, to
maximize efficacy while minimizing overlapping toxicity. Preclin-
ical optimization of appropriate drug combinations for clinical
trial in rare cancers is especially important, since the small
patient populations place severe constraints on the number of
clinical studies that can be conducted.
It is important to note that mEPEphb2 tumors model just one
(subtype-D) of nine possible subtypes of human ependymoma
(Johnson et al., 2010). Therefore, some drugs identified in the
current study may retain subtype-D specificity in humans, rather
than displaying broad antiependymoma activity; however, this
is a strength rather than a weakness of our approach. Although
many human cancers have been carved up into distinct sub-
types, these are not usually considered in the clinical trial design
because we have lacked the means to predict their sensitivity to
drugs. Consequently, clinical trials that fail to recruit adequate
numbers of treatment-sensitive patients run the risk of rejecting
useful drugs. Accurate mouse models of genomic subtypes of
cancers present the exciting opportunity tomodel human cancer
heterogeneity during preclinical drug development. To this end,
we are using the same methodology employed to produce
mEPEphb2 tumors to generate mouse models of the remaining
eight ependymoma subtypes. Together with our integrated
in vitro and in vivo screening approach, this battery of models
should allow us to complete in months, numerous single and
multidrug preclinical trials that would take decades to conduct
in the clinic. Drugs prioritized through this approach could then
be passed to definitive clinical trials.
The active agents identified in our study not only provide ther-
apeutic leads for the clinic but also insights into disease biology.
Specifically, our combined HTS and kinome-wide binding
assays of active kinase inhibitor scaffolds, have unmasked the
IGF signaling and centrosome cycle pathways as regulators of
subtype-D ependymoma. Further work will be required to define
the aberrant function and clinical significance of these pathways,
but studies of normal NSCs strongly suggest that these path-
ways are likely to be important in ependymoma. Lehtinen and
colleagues showed recently that the CSF provides a proliferative
niche for forebrain NSCs that includes IGF2 as a major constit-
uent. Specifically, they demonstrated that IGF2 present in the
CSF is bound by IGF1R expressed in the apical membranes of
NSCs, stimulating cell proliferation (Lehtinen et al., 2011). The
vast majority of ependymomas arise directly adjacent to the
ventricular system, most likely from NSCs of the SVZ (Johnson
et al., 2010; Kleihues et al., 2002; Taylor et al., 2005). Further-
more, we show here that IGF1R is upregulated in mEPEphb2 cells
relative to their parental NSCs, and that IGF2-IGF1R signaling in
these cells is blocked by drugs that inhibit their proliferation.
Considerable evidence also points to the centrosome cycle as
a critical regulator of NSC polarity, self-renewal, and proliferation
(Lesage et al., 2010). In this regard, Wang and colleaguescer Cell 20, 384–399, September 13, 2011 ª2011 Elsevier Inc. 391
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Figure 5. Kinase Inhibitors Active against mEPEphb2 Target the Centrosome Cycle and Insulin Growth Factor Signaling Pathway
(A and B) Schematics of the centrosome cycle (A) and insulin growth factor pathway (B) marked with members of the kinase inhibitor scaffold (blue boxes) and
GSK-PKIS (red boxes) libraries adjacent to their target molecules.
(C) Heatmaps reporting gene expression patterns inmouse cells and tumors (data from Johnson et al., 2010) of IGF1R, DHFR and TYMS. Figures below report the
median Log Ratio of expression for each cell or tumor type and the number in parenthesis to the right the p-value for the ANOVA of this distribution.
(D) Western blot analysis of phosphorylated and total IGF1R, AKT, and phosphorylated GSK3b and S6 species in mEPEphb2 cells treated with the IGF1R kinase
inhibitor GSK2110236A (or vehicle) followed by IGF2 stimulation.
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asymmetric division of mouse NSCs, such that the renewed
daughter inherits the maternal centriole while the new centro-
some is inherited by the differentiating daughter neuroblast
(Wang et al., 2009). Many of the inhibitors the we identified as
active against mEPEphb2 cells and NSCs, target kinases thatFigure 4. Kinome-Wide Binding Assay of Equipotent Kinase Inhibitor S
(A) Left, four kinase inhibitor scaffolds with equipotent activity in the HTS were su
kinases in the human kinome (right). Kinases bound with more than 50% activ
Reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
(B) Six-point dose-response Kd binding assays of scaffolds against selected kin
Canregulate critical steps in this process including centrosome
duplication, e.g., CDK2 and TTK; spindle orientation and centro-
some separation, e.g., PLK1; and spindle maintenance, e.g.,
GAK. Thus, the centrosome cycle is intimately related to NSC
fate and may well be disrupted and targetable in ependymoma.
We are currently working to determine the roles of PIP5K1Ccaffolds
bject to a single concentration (2.5 mM) competitive binding assay against 442
ity relative to controls are marked with labels colored according to scaffold.
ases. Boxes show the Kd values (%20 mM) for each kinase.
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Table 1. Preclinical Drug Protocols Used to Treat Mice Harboring mEPEphb2 Orthotpic Xenografts
Drug Dose (per kg) Schedule Reference
5-FU 75 mg i.v., once weekly Houghton et al., 1996
5-FU Up to 15 mg s.c., implants Kamano et al., 1997
Bortezomib 0.8 mg i.v., twice weekly Williamson, et al., 2009
Lapatinib 160 mg p.o., twice daily 5/7 days Gorlick et al., 2009
Irinotecan 10 mg i.p., once daily 3 5 days, recur every 21 days Thompson et al., 1997
Topotecan 1 mg i.p., once daily 3 5 days, recur every 21 days Stewart et al., 2004
Carboplatin 90 mg i.v., once every 21 days Tonda et al., 1996
Topotecan + carboplatin As above As above As above
i.v., intravenous; s.c., subcutaneous; i.p., intraperitoneal.
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identified in our kinome-wide binding assays but are less well
understood. Notably, PIP5K1C that bound three of four kinase
scaffolds in our screen maps to a focal amplicon that we
observed in human cerebral ependymomas (19p13.3) and has
been reported to maintain stem cell proliferation and inhibit
neuronal differentiation (Johnson et al., 2010; Wang et al.,
2007; Yu et al., 2011). Thus, this kinase is of particular interest
as a potential therapeutic target in ependymoma.
Our study also emphasizes the value of HTS for drug retooling.
5-FU is active against glioblastoma but this drug has never been
tested formally in patients with ependymoma (Grunda et al.,
2010). Indeed, in the absence of the evidence provided in the
current study, it is unlikely that an early generation chemothera-
peutic like 5-FU would ever be selected for clinical trial against
ependymoma. Therefore, HTS approaches provide us with the
opportunity to rationally repurpose cancer drugs. Well-charac-
terized and accurate models should improve the efficiency and
the confidence with which we do this. When these studies are
coupled with comprehensive pharmacokinetic studies, these
models can also help determine the most appropriate mode of
administration of repurposed drugs. Concurrent measures of
brain tumor and plasma 5-FU levels in our model suggest that
bolus administration might be a more effective way to deliver
the drug to ependymoma. Importantly, we are now using these
preclinical response and pharmacokinetic models to test com-
binations of drugs identified as most active in our single agent
HTS and in vivo studies. This includes combinations of centro-
some cycle or IGF inhibitors, with conventional cytotoxic agents
such as 5-FU. We envisage that continued pharmacokinetic and
response assessments of these combination therapies will allow
us to design the optimal schedule for translation to the clinic.
In summary, we describe an integrated, multiplatform in vitro
and in vivo HTS of ependymoma that identifies a series of biolog-
ical insights and potential therapies for clinical development. Our
mouse model allows both testing of drug efficacy in a specific
genomic subtype of the disease, and concurrent assessment
of toxicity to the parental normal NSC. The development of addi-Figure 6. In Vivo Efficacy against mEPEphb2 Ependymomas of Drugs D
Panels to the left show serial weekly bioluminescence scans of a single represent
entire cohort of mice treated with the corresponding drug(s) the mean (±SD) week
implantation. Asterisks in bar graphs of drug-treated mice report whether the fo
control group. Graphs to the right report the survival of drug- (red line) versus contr
***p = 0.0005 for the corresponding statistic. See also Figure S2.
Cantional mouse models of ependymoma subtypes should allow
further comprehensive preclinical assessment of therapies for
clinical trials tailored to all disease subtypes.
EXPERIMENTAL PROCEDURES
Isolation and Culture of Mouse NSCs andMouse Ependymoma Cells
mEPEphb2 cells, mBTNICD1 cells, and mouse embryonic cerebral NSCwt and
NSCnull were isolated and cultured in supplemented neurobasal medium
exactly as described previously (Johnson et al., 2010). mEPEphb2 cells were
tagged with luciferase by transduction with an MSCV-Luc-IRES-YFP retro-
virus. All animal studies, were approved by the St Jude Children’s Research
Hospital Animal Care and Usage Committee and performed in full compliance
with regulatory standards.
HTS
The HTS approach is described in detail in Supplemental Experimental Proce-
dures. Briefly, for primary screening cells were seeded in 30 ml of neurobasal
medium in eachwell of 384-well plates (Corning) using an automated plate filler
(Wellmate, Matrix). After 24 hr, 25 nl of solution containing appropriate
compounds were pin transferred into the 384-well plates resulting in approx-
imately 8.3 mM final drug concentration. Each plate also included DMSO
only negative controls and cyclohexamide single point (0.5 mM) and dose-
response (0.5 mM to 0.01 nM) positive controls. Cell number was determined
in each well using the Cell Titer Glo reagent (Promega) and read in an auto-
mated Envision plate reader (Perkin-Elmer) after 96 hr incubation. Lumines-
cence data were normalized by log10 transformation and the percentage
inhibition = 100 3 (sample result – negative control mean)/(positive control
mean – negative control mean) calculated. Secondary screens were con-
ducted in a similar manner although compounds were applied in a dilution
series (8.3 mM to 0.5 nM final concentration) and repeated in triplicate. All
data processing and visualization was performed using custom programs
written in the Pipeline Pilot platform (Accelrys, v.7.0.1) and the R program.
The R drc package was used to fit sigmoidal curves and ROC statistics
computed using the R rocr package. The quality of the primary screening
strategy was assessed by multiple methods including ROC analysis, Z-prime,
and other screening quality metrics (see Supplemental Experimental
Procedures).
Kinome-Wide Competitive Binding Assays
Kinome-wide binding assays were completed for kinase inhibitor scaffolds
using KINOMEscan technology through DiscoveRx. Briefly, KINOMEscan is
based on a competition binding assay that quantitatively measures the abilityisplaying Different Activities in the HTS
ative animal treated with the indicated drug(s). Central bar graphs report for the
ly fold change in tumor bioluminescence relative to levels immediately following
ld tumor bioluminescence at that time point differs from that observed in the
ol- (black line) treatedmice in each cohort. In both graphs *p = 0.05; **p = 0.005;
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Figure 7. Pharmacokinetics and In Vivo Toxicity of 5-FU
(A) Concurrent measures of intratumoral and plasma 5-FU concentrations in ten mice that each received a single intravenous injection of 75 mg/kg of drug.
(B) In vitro washout studies of 5-FU activity against mEPEphb2 cells. Cells were incubated for the indicated time period with 5-FU and then to a total of 96 hr without
drug. Dotted line denotes the concentration maintained in mEPEphb2 tumors in the brain for at least 1 hr following bolus administration.
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The assay is performed by combining three components: DNA-tagged kinase;
immobilized ligand; and a test compound. The ability of the test compound to
compete with the immobilized ligand is measured via quantitative PCR of the
DNA tag.
Ependymoma Allografts
Cells (1.53 106mEPEphb2-LUC) resuspended in 5 ml of Matrigel (BDBioScience)
were implanted into the cerebral cortex of 6- to 8-week-old CD-1 nu/nu
immunocompromised mice exactly as described (Johnson et al., 2010).
Mice were subject to daily clinical assessment of neurological function and
weekly bioluminescence. Briefly, animals were injected with 200 ml of an
aqueous solution of D-luciferin (15 mg/ml, Caliper Life Sciences) approxi-
mately 5 min prior to being imaged using an IVIS200 in vivo imaging system
(Xenogen, Caliper Life Sciences). A pseudocolor image representing light
intensity was generated and the relative light intensity (photons/second)
from each mouse was quantified using LivingImage 4.0 software (Xenogen).
For drug efficacy studies, agents were administered to mice beginning seven
days post implantation when tumor luminescence ranged from 1.7–8.0 3 107
photons/sec. Mice displaying signs of excessive morbidity or toxicity (>20%
weight loss) were euthanized.
Animals were treated with compounds as described in Table 1 and all drugs
with the exception of lapatinib were acquired as patient preparations from the
Pharmacy at St Jude Children’s Research Hospital. 5-FU, topotecan and
carboplatin were diluted to the required concentration in sterile water while
bortezomib and irinotecan were diluted in sterile PBS. Lapatinib (LC labs)
was suspended in a solution of 0.5% hydroxypropylmethylcellulose/0.1%
Tween 80 and administered by gavage.
5-FU Pharmacokinetic Studies
CD-1 nudemice agedR8weeks (23–28 g) were studied.Mice received a bolus
tail vein injection of 5-FU (75 mg/kg) and blood samples collected at 5, 15, 30,
60, and 90min post injection. For infusion studies, mice received an infusion of
5-FU (13 mg/kg/hr) via subcutaneous Alzet pumps (model 2001D; Cupertino,
CA) and blood samples were taken at 24, 48, and 72 hr post pump implanta-
tion. 5-FU levels were determined in blood samples using a modified previ-
ously described HPLC method (Alsarra and Alarifi, 2004). Penetration of
5-FU into orthotopically implanted mEPEphb2 brain tumors following intrave-
nous bolus or subcutaneous infusion was assessed using a previously pub-
lished microdialysis technique (Zhuang et al., 2006).
In Vivo Assessment of Drug Toxicity
Mice where Prom1-expressing cells are marked with LacZ (Zhu et al., 2009)
were treated with 5-FU or Bortezomib either chronically (4 weeks) or acutely
(two doses). The brains of these mice were fixed for frozen sectioning and
processed as follows by investigators blinded to treatment group. Sagittal
sections spanning the entire thickness of each brain were reviewed and three
sections selected from equivalent positions in each brain representing the
medial, mid and lateral aspects of the lateral ventricle. The three sections
from each of the three points in the lateral ventricle were stained for LacZ,
ApoTag or DCX. LacZ staining was performed and counterstained with
nuclear-fast red as described (Zhu et al., 2009). Apoptosis within the SVZ
was measured using the Apoptag fluorescein in situ apoptosis detection kit
(Millipore). DCX immunofluorescence was performed using standard
methods. Tiled images of the entire lateral ventricle were generated using a
Zeiss microscope (Axio Imager M2) and processed using AxioVision Rel 4.8.(C) Concurrent measures of intratumoral and plasma 5-FU concentrations in ten
(D) Percentage tumor:plasma AUC ratio of 5-FU delivered by 75 mg/kg bolus inj
(E) Left: Top panel shows ApoTag stained apoptotic cells in the lateral SVZ of Prom
or bortezomib treatment. Middle panels show low and high power images respect
LacZ staining of the corresponding mice. Arrows indicate cells positive for the
cp = choroid plexus, LV = lateral ventricle. Right: Graphs to the right report the patt
***p < 0.0005 relative to vehicle controls).
(F) Coimmunofluorescence of nuclear b-galactosidase expressed from the mo
ependymal cells. Panel to the right shows a Prom1+/CD24 cell (arrow) within the
CanAntibodies used include DCX (Santa Cruz #sc-8066), CD24 (BD #557436),
and LacZ (b-galactosidase, MP Biomedicals #55976).
SUPPLEMENTAL INFORMATION
Supplemental Material includes Experimental Procedures, two figures, and
one table and can be found online at doi:10.1016/j.ccr.2011.08.013.
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